Skip to main contentSkip to footer content

Our Product: Tiprelestat is a game changing innovation

Tiprelestat is a pioneering anti-inflammatory and tissue protective drug being developed for the treatment of pulmonary-arterial hypertension, the prevention of serious disease progression of COVID-19 and the prevention of postoperative inflammatory complications.

Our Vision: Natural protection smart reinvented

We at tiakis develop novel and groundbreaking therapeutic solutions in indications with high unmet medical need. 

Our drive is to make use of the human body’s own defense mechanisms to prevent tissue damage and inflammation driven complications. 

Tiprelestat - our investigational medicinal product – is being developed to be the driver of a paradigm change as a therapeutic solution in disease areas such as prevention of postoperative inflammatory complications, treatment of pulmonary-arterial hypertension and the prevention of serious disease progression of COVID-19

Mechanism of action: Tiprelestat – the tissue protective agent

  • Tiprelestat is identical to the human protein elafin and a potent reversible inhibitor of human neutrophil elastase and proteinase 3. It’s able to inhibit their activity almost completely in vitro and in vivo.

  • Tiprelestat is associated with a significantly reduced postoperative need for intensive care in patients undergoing esophageal cancer surgery.

  • Tiprelestat inhibits the formation of neutrophil exosomes and neutrophil extracellular traps, inhibits NFkB and restores pathologic bone morphogenic protein signaling.

  • Tiprelestat reduces, in vivo, vascular smooth muscle cell proliferation and vascular occlusion and promotes alveolar formation.

  • Tiprelestat suppresses reperfusion injury occurring after heart transplantation, myocardial infarction, and skeletal muscle ischemia.

  • Tiprelestat is able to revert the pathology in pulmonary arterial hypertension and to reduce ventilator induced injury.

  • Tiprelestat is well tolerated and has been subjected to numerous preclinical and clinical investigations in a variety of disease areas.

In-focus medical fields Tiprelestat

Highly invasive surgery

Such as esophageal cancer surgery

Pulmonary indications

Such as pulmonary arterial hypertension and COVID-19

Cardiovascular indications

Such as coronary artery bypass graft surgery

Pipeline: Towards progress

tiakis has driven the complete development of Tiprelestat from the discovery of human elafin at the University of Kiel to clinical proof-of-concept and has established a global network of renowned research institutes, physicians and hospitals in Europe and the US.

These are the next steps on our development path.

Indication
Discovery / Preclinical
Phase I
Phase II
Pivotal trial
Prevention of post-operative morbidity in esophageal cancer surgery
planned
Treatment of pulmonary arterial hypertension
planned
Attenuation of severe disease progression of COVID-19
planned
Please scroll/swipe to the right.

All advantages at a glance: Good reasons for Tiprelestat

Tiprelestat exhibits an excellent therapeutic benefit risk profile for the use as an anti-inflammatory and tissue protective drug.

Our development programs are focused on our late-stage indication major surgery, and our early-stage indications pulmonary arterial hypertension (PAH) and COVID-19.

In major surgery for instance, we were able to significantly reduce intensive care stays. Good for patient health and more efficient, plannable intensive care bed assignment.

We will gladly answer your questions.

Get in Contact
phone: +49 431 8888 462
email: info@tiakis.bio